The way 510(k) submissions are prepared and filed with the FDA has fundamentally changed. The electronic Submission Template And Resource (eSTAR) is now the mandatory format for 510(k) submissions, replacing the era of free-form paper and PDF compilations. For manufacturers accustomed to assembling submissions as a stack of separate documents, eSTAR represents a meaningful shift in process - and, used well, a significant opportunity to reduce review friction.
What Is eSTAR?
eSTAR is an interactive, guided PDF template developed by the FDA's Center for Devices and Radiological Health (CDRH) that walks a submitter through every required element of a premarket submission. Rather than determining the structure yourself, you complete a dynamic form that expands based on your answers, attaches supporting documents at the appropriate points, and automatically verifies that required fields and attachments are present before the submission can be finalized. The same template structure is used by FDA reviewers, creating consistency between how submissions are built and how they are assessed.
Mandatory for 510(k)s
eSTAR is now required for 510(k) submissions, including both traditional and abbreviated 510(k)s for device and in vitro diagnostic products. The De Novo classification request pathway can also be submitted via eSTAR, and the FDA has steadily expanded the template's applicability. Submissions are filed electronically through the FDA's CDRH Customer Collaboration Portal (CCP), eliminating the need for paper copies and eCopy formatting that previously caused administrative delays.
How eSTAR Reduces Refuse to Accept Holds
One of the most practical benefits of eSTAR is its effect on the FDA's Refuse to Accept (RTA) screening. Because the template performs an automated completeness check, a submission cannot be finalized with missing required elements - the very deficiencies that historically triggered the majority of RTA holds. In effect, eSTAR front-loads the administrative completeness review. This does not guarantee a substantive clearance, but it largely removes the avoidable, weeks-long delays caused by administrative gaps.
- Built-in completeness logic: The template flags empty required fields and missing attachments before submission.
- Consistent structure: Reviewers receive information in a predictable format, which can streamline review.
- Fewer formatting rejections: Electronic filing through the CCP removes eCopy and paper-formatting failure points.
What eSTAR Does Not Change
It is important to understand that eSTAR changes the format and packaging of a submission, not the substance. The underlying evidence requirements are unchanged: you still need a sound predicate strategy, a complete device description, performance testing, biocompatibility and software documentation as applicable, and a well-reasoned substantial equivalence argument. A poorly conceived regulatory strategy will not be rescued by a well-completed template. The completeness check confirms that information is present, not that it is adequate or persuasive.
Preparing an Effective eSTAR Submission
The most efficient approach is to plan the submission content against the eSTAR structure from the outset rather than retrofitting existing documents at the end. Map your testing, documentation, and labeling to the template's sections early, ensure attachments are properly formatted and named, and conduct an internal review against both the eSTAR completeness logic and the substantive expectations of your device type. For complex or novel devices, a pre-submission (Q-Sub) meeting remains valuable for aligning with the FDA before the review clock starts.
How Sequence Group Can Help
Sequence Group prepares and files eSTAR-based 510(k) and De Novo submissions end to end - building regulatory strategy, compiling and structuring content to the template, and conducting rigorous internal review before filing through the CDRH portal. Contact us to make your next FDA submission faster, cleaner, and less likely to stall.
Frequently Asked Questions
What is eSTAR and is it required for all 510(k) submissions?
eSTAR is an interactive, guided PDF template developed by FDA's CDRH that walks submitters through every required element of a premarket submission. It is now mandatory for both traditional and abbreviated 510(k)s for device and in vitro diagnostic products. The De Novo classification request pathway can also be submitted via eSTAR. Submissions are filed through the CDRH Customer Collaboration Portal.
How does eSTAR reduce Refuse to Accept (RTA) holds?
eSTAR includes built-in completeness logic that flags empty required fields and missing attachments before a submission can be finalized. This front-loads the administrative completeness check that FDA reviewers would otherwise perform during the 15-business-day RTA screening, removing the avoidable delays caused by administrative gaps. It does not guarantee substantive clearance - the quality of the underlying evidence still determines the outcome.
Does switching to eSTAR change what evidence I need to include in my 510(k)?
No. eSTAR changes the format and packaging of a submission, not the substance. The underlying requirements - a sound predicate strategy, complete device description, performance testing, biocompatibility documentation, software documentation as applicable, and a well-reasoned substantial equivalence argument - are unchanged. The completeness check confirms that information is present, not that it is adequate or persuasive.